Occlutech manufactures and commercializes high-quality and versatile occluders to provide easier and safer treatments for patients with structural heart diseases. The benefits of our medical devices accelerate the shift from open heart surgery to minimally-invasive options as the standard of care for these patients. Occlutech is well recognized by industry experts for leading in product strategies including product quality, price/performance value, product differentiation and breadth of product line that enhance customer value and customer experience.
Occlutech provides a full product line to solve problems such as atrial septal defect (ASD), patent foramen ovale (PFO), paravalvular leak (PLD), patent ductus arteriosus (PDA) and ventricular septal defect (VSD) occluders. Our new left atrial appendage occluder (LAA) obtained CE registration end of May, 2016. Our devices have different configurations that are specific to individual disease abnormalities and are available in multiple sizes for a range of morphologies and anatomies. The broad, flexible and versatile solutions enable physicians to treat many patients that were not previously eligible for minimally-invasive structural heart procedures, reducing the number of patients that ultimately require open-heart surgery.
ManagementHerr Tor Peters
Herr Dr. Francisco J. Morales Serrano
Year of establishment2003
Employees60 in Germany, 130 worldwide
Business activityManufacture, research, development and sales of cardiovascular medical products and accessories for use in the minimally-invasive treatment of structural heart defects.